Trade Name: DESBAC SUSPENSION
Generic Name:
Cefpodoxime proxetil USP Suspension
Presentation:
Desbac Capsule: Each
capsule contains Cefpodoxime Proxetil USP 130 mg equivalent to Cefpodoxime 100
mg.
Desbac Suspension: Each 5
ml reconstituted suspension contains Cefpodoxime Proxetil USP equivalent to
Cefpodoxime 40 mg.
Indication:
Cefpodoxime is indicated for the
treatment of the following diseases:
-
Upper respiratory tract
infections: Acute otitis media, Sinusitis, Pharyngitis and Tonsillitis
-
Lower respiratory tract
infections: Acute community-acquired pneumonia, Acute bacterial exacerbation
of chronic bronchitis
-
Upper & lower urinary tract
infections: Cystits, Pyelonephritis
-
Skin & soft tissue infections:
Abscesses, Celluli9tis, Infected wounds, Furuncles, Folliculitis, Paronychia,
Carbuncles and Ulcers
-
Sexually transmitted diseases:
Acute uncomplicated urethral & cervical gonorrhea, Acute ano-rectal infections
in women caused by N.gonorrhoeae
Dosage and administration:
Adults (>13 years):
|
Type of infections |
Total daily dose |
Dose frequency |
Duration (Days) |
|
Acute, community-acquired pneumonia |
400mg |
200
mg 12 hrly |
14 |
| Acute
bacterial exacerbation of chronic bronchitis |
400mg |
200
mg 12 hrly |
10 |
|
Uncomplicated gonorrhea (men & women) |
200mg |
Single dose |
|
|
Rectal gonococcal Infections ( Women ) |
200mg |
Single dose |
|
| Skin
and skin structure |
800mg |
400
mg 12 hrly |
7-14 |
|
Pharyngitis/tonsillitis |
200mg |
100
mg 12 hrly |
5-10 |
|
Uncomplicated UTI |
200mg |
100
mg 12 hrly |
7 |
Children:
| 15 days - 6 month |
: |
8 mg/kg/day in tow divided doses |
| 6 month - 2 years |
: |
5 ml twice daily |
| 3 - 8 years |
: |
10 ml twice daily |
| Above 9 years |
: |
12.5 ml or 100 mg capsule twice
daily. |
| |
|
|
Contraindications:
Cefpodoxime Proxetil is
contraindicated in patients with a known allergy to Cefpodoxime or to the
Cephalosporin group of antibiotics.
Precautions:
The total daily dose of
Cefpodoxime Proxetil should be reduced in patients with transient or persistent
reduction in urinary output due to renal insufficiency. Cefpodoxime should be
administered with caution to patients receiving concurrent prolonged use of
Cefpodoxime Proxetil may result in overgrowth of non-susceptible organisms.
Repeated evaluation of the patient's condition is essential.
Use in pregnancy and lactation:
Cefpodoxime was neither
teratogenic nor embryocidal in animal trial. There is, however, no adequate and
well-controlled study of Cefpodoxime Proxetil use in pregnant women. The drug
should be used during pregnancy only if clearly needed. As Cefpodoxime is
excreted in human milk, a decision should be made whether to discontinue
breast-feeding of to discontinue the drug.
Side-effects:
Cefpodoxime is generally well
tolerated. Possible side effects include gastrointestinal disorders such as
diarrhoea, nausea, vomiting, abdominal pain, rash, urticaria and itching.
Occasional cases have been reported of headaches, dizziness, tinnitus,
parenthesis, asthenia, and malaise.
Drug interactions:
Antacid: Concomitant
administration of high doses of antacids ( sodium bicarbonate and aluminum
hydroxide ) of H2 blockers reduces peak plasma level by 24% to 42%
and the extent of absorption by 27% to 32% respectively.
Probenecid: Renal
excretion of Cefpodoxime was inhibited by probenecid and resulted in an
approximately 31% increase in AUC and 20% increase in peak Cefpodoxime levels.
Nephrotoxic drugs : Close
monitoring of renal function is advised when Cefpodoxime proxetil is
administered concomitantly with compounds of known nephrotoxic potential.
Commercial Pack:
Desbac Capsule: Each box
contains 3 alu-alu blister strips of 4 Capsules.
Desbac Suspension: Each bottle contains cefpodoxime proxetil powder to be
reconstituted into 50 ml suspension.
|
